Drugs / LDAC administered subcutaneously (SC)
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04891757 | Jun 2021 → Sep 2025 overdue | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | Foghorn Therapeutics Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LDAC administered subcutaneously (SC) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04891757 ↗ |
| Known as | LDAC | “LDAC” NCT04891757 ↗ |
| Route | Subcutaneous | “LDAC administered subcutaneously (SC)” NCT04891757 ↗ |